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Background: Cancer-specific survival (CSS) within high-risk non-metastatic prostate
cancer varies dramatically. It is likely that within this heterogenous population there
are subgroup(s) at extraordinary risk, burdened with an exaptational poor prognosis.
Establishing the characteristics of these group(s) would have significant clinical
implications since high quality preoperative risk stratification remains the cornerstone
of therapeutic decision making to date.
Objective: To stratify high-risk prostate cancer based on preoperative characteristics
and evaluate cancer specific survival after radical prostatectomy.
Method: The EMPaCT multi-center database offers an international population of
non-metastatic high-risk prostate cancer. Preoperative characteristics such as age,
biopsy Gleason score, PSA and clinical stage were subcategorized. A multivariate
analysis was performed using predictors showing significant survival heterogeneity after
stratification, as observed by a univariate analysis. Based upon the hazard ratios of this
multivariate analysis, a proportional score system was created. The most ideal group
distribution was evaluated trough different score cut-off’s. The predictive value was tested
by the herald C index.
Results: An overall 5-years CSS of 94% was noted within the entire high-risk cohort
(n = 4,879). Except for age, all preoperative risk factors showed a significantly differing
CSS. Multivariate analysis indicated, T4 stage as being the strongest predictor of CSS
(HR: 3.31), followed by ISUP grade 5 group (HR 3,05). A score system was created by
doubling the hazard ratios of this multivariate analysis and rounding off to the nearest
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complete number. Multivariate analysis suggested 0, 4, 8, and 12 pts as being the most
optimal group distribution (p-value: 0.0015). Five-years CSS of these groups were 97,
93, 87, and 70%, respectively. The calculated Herald C-index of the model was 0.77.
Conclusion: An easy-to-use pre-operative model for risk stratification of newly
diagnosed high-risk prostate cancer is presented. The heterogeneous CSS of high-risk
non-metastatic prostate cancer after radical prostatectomy is illustrated. The model
is clinically accessible through an online calculator, presenting cancer specific survival
based on individualized patient characteristics.
Keywords: prostate, prostate cancer, EMPACT, risk stratification, high risk prostate cancer
INTRODUCTION
Prostate cancer (PCa) is the second most common cancer among
men. It represents the 5th most frequent cause of cancer related
death (1). According to the WHO cancer report (2014), 1.1
million men received a new diagnosis of prostate cancer in
2012 causing 0.3 million disease related deaths (2). Since the
introduction of PSA screening in the beginning of the 80’s an
impressive incidence rise has been observed. Fortunately, this
trend was counterbalanced by a reduction in mortality since the
90’s due to earlier detection and improved curative treatments.
Nevertheless, mortality attributed to PCa is expected to rise
in the following decades implying an expanding burden to
society (3).
Non-metastatic PCa is prognostically stratified as low,
intermediate or high-risk as suggested by D’Amico in 1998
(4, 5). Currently, management of non-metastatic prostate cancer
includes active surveillance, radical prostatectomy (RP) with
or without pelvic node dissection and radiotherapy (RT) with
or without androgen deprivation therapy (ADT). As illustrated
by the PROTECT-Trial, no significant difference in low to
intermediate risk Pca specific mortality was observed between
RP and RT over a 10-years period (6). However, PCa specific
mortality was low. Although low risk prostate cancer is most
prevalent and known to have a good prognosis, high risk prostate
cancer is less frequent but contributes most to PCa specific
death (6).
Depending on fitness, low risk PCa is manageable trough
active surveillance or radical prostatectomy (RP) without lymph
node dissection (LAD). RP has shown to significantly reduce the
overall mortality of Intermediate-risk prostate cancer (IRPCa)
(7). If probability of lymph node invasion exceeds 5%, an
additional extended LAD is recommended (4). Although general
consensus concerning treatment of high-risk PCa is lacking, a
multimodal strategy including RPwith extended LAD is accepted
by our in-house protocol (4).
High-risk PCa, according to the national comprehensive
cancer network (NCCN), is defined as Gleason score ≥8, PSA >
20 ng/ml or clinical stage ≥T3a (8). Interestingly the EAU differs
from this as it defines high-risk PCa starting at a T2c clinical
stage (4). An overall established definition of high-risk disease
is thus lacking. Remarkably, metastasis free survival (MFS)
varies from 70 to 95% and 10-years biochemical recurrence
(BCR) shows a variability of 50% (5, 9). Efforts to dissect this
heterogeneity have been undertaken, as illustrated by Joniau
et al. (10).
High quality risk stratification remains the cornerstone of
therapeutic decision making. This retrospective study aims to
stratify non-metastatic PCa into subgroups showing significantly
differing CSS. Through this stratification, we aim to identify and
correlate patient and tumor related characteristics so individual




The European Multicenter Prostate Cancer Clinical and
Translational (EMPaCT) research database served as the source
for our patient cohort. This International research database
contains 9,167 men from 14 institutions who underwent radical
prostatectomy for non-metastatic high-risk PCa between 1986
and 2016. Each institution acted in accordance of their own
standards, indications and treatment protocols. Since only
patients with complete datasets could be included, the criteria
for exclusion were defined as: lacking a preoperative PSA
(n:121), absent Gleason biopsy score (n:1,070), incomplete
staging (n:1,966) and lost to follow up (n:1,014). Staging was
in accordance with the 2002 TNM system. All biopsies were
evaluated by an experienced pathologist in each respective
center. Follow up was defined as an annual clinical control with
serum PSA measurement. Cancer related deaths were judged
by the treating urologist or oncologist. Adjuvant and salvage
therapies were admitted on individual bases and institutional
preferences. From this eligible cohort, all high-risk (PSA ≥
20 ng/ml and/or GS ≥ 8 and/or cT ≥ T2c) patients were
identified and included (Figure 1).
Statistical Analysis
Preoperative prognostic variables were identified and stratified
into subcategories. PSA was subcategorized into a <20 ng/ml,
a 20 ng/ml−50 ng/ml and a >50 ng/ml. Clinical stage was
divided into T1, T2, T3a, and T3b+T4 categories. Biopsies were
categorized by the international Society of Urological Pathology
(ISUP) grading. Finally, a primary Gleason grade 5 subcategory
was created and age was stratified into <60, 60–69, and ≥70
years old. A univariate analysis of these preoperative variables
was performed to evaluate their impact on CSS. A multivariate
Frontiers in Oncology | www.frontiersin.org 2 March 2020 | Volume 10 | Article 246
Chys et al. Risk Stratification Prostate Cancer: EMPaCT
FIGURE 1 | Patient selection EMPaCT database.
cox regression analysis was performed using the significant
variables. Based on the hazard ratio’s (HR), a proportional
score system was created. Multiple cut-off values were tried
and different possibilities were compared by multivariate cox
regression analysis. The most appropriate model was selected
and its prognostic value was calculated using the concordance
index (C-index). All univariate and multivariate analyses were
performed using MedCalc Statistical Software version 17.9.7
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(MedCalc Software bvba, Ostend, Belgium). The C-index was
calculated using SAS-software version 9.4 (SAS Institute Inc.,
Cary, NC, USA). P < 0.05 were considered to be significant.
RESULTS
Study Population
Four thousand eight hundred seventy-nine men met the criteria
for final inclusion. A mean follow-up of 60.5 months was noted
with an interquartile range of 65 months (21–84 months). The
TABLE 1 | Characteristics of study population.
Included patient cohort characteristics n = 4,879
Age
Mean (SD) 64.9 (6.8)
Median (IQR) 65 (60–70)
PSA (ng/ml)
Mean (SD) 22.7 (41.6)
Median (IQR) 13 (7–27)
<20 µg/l 2,859 (58.6)
20–50 µg/l 1,415 (29)
>50 µg/l 373 (7.6)










biopsy Gleason score, n (%)





3 + 5 156 (3.2)
4 + 4 1,116 (22.9)





4 + 5 608 (12.5)







N.O.S, not otherwise specified.
TABLE 2 | Multivariate analysis of preoperative risk factors.
P-value Exp(b) Points
PSA <20 ng/ml Reference 0
20–50 ng/ml 0.03 1.43 3
>50 ng/ml <0.0001 2.81 6
Clinical stage ≤T3b Reference ≤T3b
T4 0.01 2.73 6
ISUP ≤3 Reference 0
4 0.0001 2.21 4
5 <0.0001 3.05 6
Any ISUP with primary grade 5 <0.0001 7.17 14
Bold values statistically significant P < 0.05.
mean PSA amounted to 22.7 ng/ml (0–1,710 ng/ml). A biopsy
Gleason Score of <7 was most prominent within HRPC. Clinical
stage cT3 showed most prevalent, constituting 37.5% of all high-
risk cases. An overview of the characteristic of the population is
given in Table 1. The 5, 10, and 15-years CSS were 94, 89.5, and
84.6%, respectively.
Univariate Analysis
PSA, clinical stage, Gleason biopsy score, age and the presence
of a Gleason grade 5 underwent categorization and univariate
analysis for cancer specific survival as primary outcome
(Figure 2). PSA was divided into three groups: <20, 20–50,
and more than 50 ng/ml. Gleason score was categorized by the
ISUP groups. Clinical stage was divided into four groups: T1,
T2, T3a+b, and T4. Three age groups were identified by cut-off
values of 60 and 70 years old. Finally, the presence of a primary
Gleason grade 5 was dichotomised as present or absent. Except
for age, all subdivisions of these preoperative risk factors showed
significantly differing CSS.
Multivariate Analysis
The preoperative risk factor groups which showed a significantly
differing CSS were included in a multivariate cox regression
analysis (Table 2). Biopsy characteristics were clearly the
strongest CSS predictor. The presence of a primary Gleason grade
5 (HR: 7.17), followed by ISUP grade group 5 (HR: 3.05).
Multiple combinations of clinical staging were tried in the
multivariate analysis. However, only T4 showed a significantly
different CSS as is illustrated in Figure 2D.
Based upon the hazard ratios from the multivariate analysis,
a proportional score was determined for each subgroup. This
score system was then applied to all patients. Score-based groups
were identified who showed significant differing CSS. Different
cut-offs were evaluated. After multivariate analysis the 0–4, 5–8,
9–12, and >12 pts was selected as being the optimal distribution
due to strongly differing CSS between all groups (p < 0.0001)
(Figure 3, Table 3). Five-years CSS of these groups were 97.4,
92.8, 85.2, and 72.2%, respectively.
Score Validation
In order to assess the predictive value of this score system,
the concordance index (c-index) was determined. A value of
0.77 was noted, implying a good correlation between the model
determined subgroups and the CSS. The model is accessible
online through as an easy-to-use clinical tool. (https://app.
calculoid.com/?#/calculator/41236).
DISCUSSION
When confronted with a new diagnosis of non-metastatic
prostate cancer, it is common to divide patients into low-,
intermediate- and high-risk subgroups (4). These groups are
known to harbor a significantly differing prognosis. To date,
this risk stratification remains the cornerstone of therapeutic
decision making. Although there is no discussion concerning
the need for surgical treatment in the high risk group, CSS is
known to vary strongly thus suggesting this group to be quite
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FIGURE 2 | Univariate analysis of stratified preoperative risk factors: presence of a biopsy Gleoson grade 5 (A), PSA (B), age (C), clinical stage (D), and ISUP
group (E).
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TABLE 3 | Ten-years CSS, blue line: 0–4 pts, green line: 5–8 pts, orange line 9–12 pts, red line: >12 pts.
Number at risk
0 months 20 months 40 months 60 months 80 months 100 months 120 months
0–4 pts 3,301 2,646 1,991 1,473 1,059 731 529
5–8 pts 906 644 434 279 189 114 86
9–12 pts 518 345 196 106 59 33 16
>12 pts 104 55 32 15 8 4 4
FIGURE 3 | Ten-years CSS, blue line: 0–4 pts, green line: 5–8 pts, orange line
9–12 pts, red line: >12 pts.
heterogeneous (5). This can easily be illustrated by observing CSS
after categorization by the number of high-risk factors. Intuitively
a poorer prognosis is observed in patients showing multiple
high-risk factors (Figure 4).
Historically, tumors with unfavorable characteristics (PSA
> 100 ng/ml, Gleason Score 9–10, T4 or cN1) were not
considered ideal candidates for surgery (8). This is largely
due to fear for occult metastasis, which is not yet detectable
by conventional staging technology at a given time. However,
favorable results have been achieved in surgical treatment for
non-metastatic, hormonal sensitive locally advanced prostate
cancer (11).
Previous efforts have been undertaken to stratify high-risk
PCa (9, 10). The capability to distinguish good from poor surgical
candidates remains critical in clinical practice.
Sundi et al. illustrated that the presence of a primary grade
5 on biopsy, or ≥5 cores showing a Gleason score 8–10 were
predictive for a significantly increased risk of metastasis and
cancer specific mortality (5). Unfortunately, no data concerning
number of positive biopsy cores is available in the EMPaCT
database. However, univariate analysis of ISUP grading and
presence of a primary Gleason grade 5 clearly shows its
independent and strong prognostic significance. Thus, our
findings are similar to Sundi et al.’s observation.
It has been suggested that PSA is a less valuable predictor
(10, 12). Gontero et al. illustrated that, although prognosis
diminishes with rising PSA, no absolute upper limit for radical
prostatectomy exists (12). This biomarker is susceptible to a
couple of difficulties. Firstly, it is a continuous variable. A clear
cut-off is lacking. Secondly, our results suggest that PSA harbors
the weakest CSS prognostic predictive value (HR 1.48). Only
very high PSA values (>50 ng/ml) are good predictors for poor
CSS (HR 2.97). These findings thus align with general belief that
this biochemical marker should not be decisive in therapeutic
decision making, except if extremely elevated.
Although age showed no independent value in the univariate
analysis of CSS, it is very important in therapeutic decision
making since age is mostly inversely proportional to general
fitness. unfortunately, our data and model has no eye for
comorbidity such as a Charlson score since this information was
only available for a minority of patients.
Further evaluation shows that higher scoring patients were
more likely to need adjuvant therapy such as androgen
deprivation therapy, radiotherapy or both. Furthermore, we
were able to illustrate that this score system proportionately
correlates with positive surgical margins and lymph node
invasion (Table 4).
This model was created as a tool to aid the clinician in
estimating the CSS within the heterogeneous high-risk PCa
group. It is able to distinguish those who will fare well from those
who will benefit poorly from RP, irrespective of future need for
adjuvant therapy. It can thus help tilt the scale toward more or
less intense treatment based uponmore detailed high-risk patient
and tumor characteristics.
Remarkably, the lowest score category (0–4 pts) makes
up a very significant part of the entire cohort (n = 3,186;
65.3%). This implies that practitioners are already intuitively
capable of selecting the best from the worst within the high-
risk Pca group. This selection bias is a major explanation for
the favorable 5- and 10-years CSS of the general high-risk
PCa cohort.
The magnitude of this international multi-center patient
cohort is undoubtable the major strength of this study.
Compromising more than 20 years of interinstitutional data
collection, each center treated patients according to their
own protocol and standards. This presents a more realistic
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FIGURE 4 | Prostate cancer–specific survival for the extended model with seven subgroups of high-risk prostate cancer patients (10).
TABLE 4 | Need for (neo)adjuvant therapy, positive surgical margins, and lymph node invasion.
n Neoadjuvant therapy (ADT) Adjuvant therapy (ADT/ADT+RT/RT) surgical margins: R1 + Positive lymph nodes: N+
0–4 pts 3,301 454 13.7% 738 22.4% 971 29.4% 744 22.5%
5–8 pts 906 160 17.6% 354 39.1% 424 46.7% 346 38.2%
9–12 pts 518 128 24.7% 253 48.9% 292 56.4% 260 50.2%
>12 pts 104 35 33.6% 62 59.6% 71 68.3% 62 59.6%
Stratified by model subgroups.
reflection of general population and practice. Secondly, this
subcategorization of established preoperative high-risk factors
enables a more accurate prediction of CSS after RP, thus helping
to identify those with good prospects after surgery. Thirdly, by
using ISUP grading we follow the new pathological classification.
Finally, the model is made clinically accessible through an easy-
to-use online calculator.
This study is however not without limitations. Firstly, a
retrospective study has inherent limitations due to variable data
quality. Secondly, the EMPaCT database consists only of men
treated by RP, thus a selection bias of fit men is inevitable.
thirdly, no data was available concerning the number of positive
cores in biopsy samples, as suggested by Sundi et al. Finally,
interinstitutional variability impedes standardization.
CONCLUSION
By subdividing the established preoperative high-risk factors
for prostate cancer, a new model is presented. The extended
stratification provides a more accurate prediction of CSS after
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radical prostatectomy for non-metastatic high-risk prostate
cancer. A free online calculator is offered to simplify clinical use.
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